Plus Therapeutics Inc (PSTV) News
Track canonical SquawkNews coverage tagged to PSTV, Plus Therapeutics Inc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Cerenome (PSTV) inks HCSC in-network deal, expands CNSide® coverage
Cerenome secures an in-network agreement with Health Care Service Corporation, expanding its CNSide® contracted coverage to over 150 million covered lives.
MNA | Aug 13, 2026, 11:30 AM UTC
H
PSTV Launches Cerenome
PSTV launches CNS oncology company
EQUITY | Jul 31, 2026, 12:30 PM UTC
L
PSTV - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - Click For R
PSTV - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
EQUITY | Jul 28, 2026, 11:30 AM UTC
H
Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Pr
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026,
EARNINGS | Jul 21, 2026, 11:35 AM UTC
L
PSTV plus Therapeutics and genomic testing cooperative partner to integrate next-generation sequencing into the cnside® csf assay platform
PSTV plus Therapeutics and genomic testing cooperative partner to integrate next-generation sequencing into the cnside® csf assay platform
EQUITY | Jul 16, 2026, 11:33 AM UTC
H
Plus Therapeutics Announces Name Change To Cerenome, With Nasdaq Trading Under Symbol 'CNSY,' Effective August 3; Reaffirms FY26 Milestone A
Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit. Plus will host a business update conference call and webcast today at
EARNINGS | Jun 30, 2026, 11:38 AM UTC
M
PSTV: Strikes Deal
CNSide Diagnostics, a subsidiary of Plus Therapeutics, strikes deal with Elevance Health to offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay
EQUITY | Jun 25, 2026, 11:35 AM UTC
M
PSTV Secures Coverage
Plus Therapeutics secures national coverage agreement with Elevance Health for CNSide cerebrospinal fluid assay for metastatic CNS cancer
EQUITY | Jun 25, 2026, 11:30 AM UTC
M
PSTV Updates Guidance
Plus Therapeutics to provide business update call on June 30, 2026, to discuss mid-year progress and strategy
EARNINGS | Jun 23, 2026, 11:31 AM UTC